Is Torsemide Superior to Furosemide (Lasix)?
No, torsemide is not superior to furosemide for mortality or quality of life, though it may modestly reduce heart failure hospitalizations at the cost of increased acute kidney injury risk.
Guideline Recommendations
The 2022 ACC/AHA/HFSA Heart Failure Guidelines do not prioritize one loop diuretic over another 1. Both furosemide and torsemide are listed as acceptable loop diuretics with different dosing ranges and durations of action. The guidelines note that "some patients respond more favorably to other agents in this category (e.g., bumetanide, torsemide), potentially because of their increased oral bioavailability" 1, but this is presented as a consideration for individual response rather than a blanket recommendation for superiority.
The guidelines emphasize that loop diuretics relieve symptoms but have uncertain effects on morbidity and mortality (except for mineralocorticoid receptor antagonists) 1. This is a critical point: diuretics should never be used in isolation but always combined with guideline-directed medical therapy that actually reduces hospitalizations and prolongs survival.
The Definitive Evidence: TRANSFORM-HF Trial
The TRANSFORM-HF trial (2023) is the highest quality and most recent evidence directly addressing this question 2. This pragmatic, randomized trial of 2,859 patients hospitalized for heart failure across 60 U.S. hospitals found:
- No difference in all-cause mortality over 12 months
- No difference in quality of life measured by Kansas City Cardiomyopathy Questionnaire (adjusted mean difference 0.06,95% CI -2.26 to 2.37, P=0.96) 2
- No difference in depression screening scores 2
- Results were consistent regardless of ejection fraction, NYHA class, or previous loop diuretic use 2
This trial definitively answers the question for patient-centered outcomes that matter most: torsemide does not improve how patients feel or how long they live compared to furosemide.
Hospitalization Outcomes: Mixed Evidence
Meta-Analyses Show Modest Reduction in HF Hospitalizations
Recent meta-analyses suggest torsemide may reduce heart failure-specific hospitalizations:
- 2024 meta-analysis found torsemide reduced HF hospitalizations (RR 0.60,95% CI 0.43-0.83) and cardiovascular hospitalizations (RR 0.72,95% CI 0.60-0.88), but no difference in all-cause hospitalizations or mortality 3
- 2025 meta-analysis found no difference in all-cause mortality (RR 0.98,95% CI 0.87-1.10) or all-cause rehospitalization (RR 0.95% CI 0.88-1.02) 4
Real-World Data Shows Increased Acute Kidney Injury Risk
A 2025 Medicare study of 328,640 older adults found torsemide was associated with:
- Slightly lower composite risk of HF hospitalization/death (HR 0.97,95% CI 0.95-0.99) - clinically marginal benefit
- Significantly increased acute kidney injury risk (HR 1.12,95% CI 1.10-1.15; 37 additional AKI events per 1000 person-years) 5
This trade-off is critical: any modest hospitalization benefit must be weighed against tangible kidney injury risk.
The Pharmacokinetic Myth Debunked
The 2025 TRANSFORM-Mechanism trial directly tested the theoretical pharmacokinetic advantages of torsemide 6:
- Torsemide had lower kidney bioavailability (17.1% vs 24.8%, P<0.001) - the opposite of what was expected
- Furosemide had longer duration of kidney drug delivery and natriuresis
- The commonly used 2:1 dose conversion (40mg furosemide:20mg torsemide) resulted in excessive natriuresis with torsemide
- Higher torsemide doses caused greater neurohormonal activation (increased renin, aldosterone, norepinephrine) and kidney dysfunction 6
- Despite greater natriuresis, no improvement in plasma volume or body weight occurred with torsemide
This mechanistic study explains why torsemide doesn't translate to better clinical outcomes: the kidney compensates for excessive diuresis through neurohormonal activation, negating any theoretical advantage.
Clinical Algorithm for Loop Diuretic Selection
Start with furosemide as the default loop diuretic for most patients with heart failure 1:
- It is the most studied, least expensive, and has equivalent mortality/quality of life outcomes
- Use 20-40mg once or twice daily initially, titrating to 600mg maximum daily dose 1
Consider switching to torsemide only in these specific scenarios:
- Recurrent HF hospitalizations despite optimized furosemide dosing - modest reduction in HF-specific admissions may justify the switch 3
- Documented poor oral absorption with furosemide - though the TRANSFORM-Mechanism trial questions this advantage 6
- Patient preference for once-daily dosing - torsemide's 12-16 hour duration vs furosemide's 6-8 hours 1
Monitor closely for acute kidney injury if using torsemide, especially in older adults 5.
Never use torsemide expecting:
Critical Pitfalls to Avoid
Don't overdose torsemide: The common 2:1 conversion ratio (40mg furosemide = 20mg torsemide) causes excessive natriuresis. A 4:1 ratio (40mg furosemide = 10mg torsemide) produces equivalent natriuresis 6
Don't use loop diuretics in isolation: They relieve symptoms but don't reduce mortality. Always combine with GDMT (ARNI/ACEi/ARB, beta-blockers, MRAs, SGLT2 inhibitors) 1
Don't ignore the kidney injury signal: Torsemide increases AKI risk by 12% - monitor creatinine closely 5
Don't expect better decongestion: Despite theoretical advantages, torsemide doesn't improve fluid status due to compensatory neurohormonal activation 6
The Bottom Line for Clinical Practice
Furosemide remains the appropriate first-line loop diuretic for heart failure based on equivalent mortality, quality of life, and lower acute kidney injury risk. Torsemide may modestly reduce heart failure hospitalizations in select patients with recurrent admissions, but this comes at the cost of increased kidney injury and no improvement in how patients feel or how long they live. The 2024 European guideline commentary correctly notes that loop diuretics "relieve symptoms, but there is no evidence that they reduce the risk of rehospitalizations and prolong life in HF" 7 - this applies equally to both agents.